Merck Wards Off More Januvia Infringers In India

Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export two of its diabetes therapies, or hope to introduce copies of these on the domestic market, infringing on its patents.

MSD India (as Merck & Co. Inc. is known outside of the US and Canada) has initiated legal proceedings against several Indian parties that are claimed to be producing its diabetes products Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), securing ex-parte injunctions from the Delhi High Court in two cases.

One of the alleged infringers, Mahaveer Chand, is said to be involved in contract manufacturing and export of generic version...

More from India

More from Focus On Asia